Search Results 2561-2570 of 18408 for rheumatoid arthritis

  1. Overview - Neurobiology of Alzheimer's Disease and Related Dementias - Mayo Clinic Research

    The team seeks to understand why APOE2 contributes to longevity and protects against Alzheimer's disease; whereas, APOE4 is the strongest genetic risk factor ...

  2. Program on Physician Well-Being - Research Translated Into Strategies in Practice

    ... factor loading on the emotional exhaustion and depersonalization subscales of the Maslach Burnout Inventory. The two items have been validated in a sample ...

  3. Publications - Steven Attia, D.O. - Mayo Clinic

    ... Factor Pathway in Angiosarcoma. Front Oncol. 2018; 8:71 Epub 2018 Mar 22. View PubMed; Bagaria SP, Chang YH, Gray RJ, Ashman JB, Attia S, Wasif N. Improving ...

  4. Postherpetic neuralgia - Symptoms and causes - Mayo Clinic

    This complication of shingles can cause pain, itching and numbness long after the shingles rash clears. Treatments can ease symptoms.

  5. https://college.mayo.edu/sitemap.xml

    ... rheumatology-fellowship-minnesota/</loc> <changefreq>daily</changefreq> <priority>1</priority> <lastmod>2025-09-20 11:18:50</lastmod> </url> <url> <loc> ...

  6. A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma - Mayo Clinic

    ... factor (GMCSF) and a novel bifunctional short hairpin RNAi (bi-shRNAi) targeting furin convertase, thereby downregulating endogenous immunosuppressive ...

  7. Knee Biologic Preservation: Functional and Clinical Outcome

    Arthritis; Infection. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to-date information ...

  8. Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorder - Mayo Clinic

    Hematopoietic growth factors: ≥ 14 days after the last dose of a long-acting growth factor (e.g., Neulasta) or 7 days for short-acting growth factor; for ...

  9. Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma - Mayo Clinic

    ... factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to study treatment. Patient ...

  10. Health Topics - Mayo Clinic News Network

    Consumer Health: What do you know about these 3 rare rheumatic diseases? Laurel Kelly. September 14, 2022. First · Previous ... 192 · 193 · 194 · 195 · 196 ...